

**From:** Krissy.Carrington@sanofi.com [mailto:Krissy.Carrington@sanofi.com]  
**Sent:** Monday, July 23, 2018 12:49 PM  
**To:** Hoffman, Kelsy <Kelsy.Hoffman@fda.hhs.gov>  
**Subject:** RE: STN 125563 Advice and Information Request

Dear Kelsy,  
Acknowledging receipt of this IR. Kind regards,  
Krissy

**From:** Hoffman, Kelsy [mailto:Kelsy.Hoffman@fda.hhs.gov]  
**Sent:** Monday, July 23, 2018 12:20 PM  
**To:** Carrington, Krissy /CA  
**Subject:** [EXTERNAL] STN 125563 Advice and Information Request

Dear Ms. Carrington,

Please note that BLA 125563/0, "Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine," cannot be approved until a complete response is received for the companion For Further Manufacturing Use (FFMU) applications that you cross-reference for information regarding the Haemophilus b Conjugate (Meningococcal Protein Conjugate) Bulk Intermediate and Hepatitis B Vaccine (Recombinant) Bulk Intermediate.

Also, we note that although cross-reference authorization letters were submitted to FFMU BLAs 125580/0 and 125581/0 for BLA 125563/0, cross-reference letters to the FFMU BLAs were not officially submitted to BLA 125563/0. Please submit official cross-reference letters under module 1.4 of your BLA.

Please let me know if you have any questions.

Thank you,  
Kelsy

**Kelsy F. Hoffman, Ph.D.**  
**LCDR, USPHS**  
Center for Biologics Evaluation and Research  
Office of Vaccines Research and Review  
U.S. Food and Drug Administration  
Tel: 301-796-2640  
[Kelsy.Hoffman@fda.hhs.gov](mailto:Kelsy.Hoffman@fda.hhs.gov)



---

*THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE*

*UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.*